“To me the combination of CETSA with mass spectrometry is the most exciting thing that has happened in drug discovery and proteomics in a long time.” 

Mikhail Savitski, Group Leader and Head of the Proteomics Core Facility at EMBL Heidelberg and former Group Leader in Experimental Bioinformatics at Cellzome GmbH (a GSK company)

“CETSA is an exciting technology that will allow us to examine the interaction between a drug candidate and its protein target within the cell. We are pleased to be exploring the potential of this platform in an open collaboration with the scientists at Pelago.”

Mike Snowden, Vice President Discovery Sciences at AstraZeneca

“We believe that the CETSA method may hold promise within our research at Pfizer, and we look forward to working with our counterparts at Pelago.” 

Mark Bunnage, Vice President, Worldwide Medicinal Chemistry at Pfizer